| Title: | Effects of electrochemotherapy on immunologically important modifications in tumor cells |
|---|
| Authors: | ID Kešar, Urša (Author)
ID Markelc, Boštjan (Author)
ID Jesenko, Tanja (Author)
ID Uršič Valentinuzzi, Katja (Author)
ID Čemažar, Maja (Author)
ID Strojan, Primož (Author)
ID Serša, Gregor (Author) |
|---|
| Files: |  URL - Source URL, visit https://www.mdpi.com/2076-393X/11/5/925
 PDF - Presentation file, download (7,17 MB)
MD5: 43961FF3470868C06D61B106DF01FCD7
|
|---|
| Language: | English |
|---|
| Typology: | 1.01 - Original Scientific Article |
|---|
| Organization: |  OI - Institute of Oncology
|
|---|
| Abstract: | Electrochemotherapy (ECT) is a clinically acknowledged method that combines the use of anticancer drugs and electrical pulses. Electrochemotherapy with bleomycin (BLM) can induce immunogenic cell death (ICD) in certain settings. However, whether this is ubiquitous over different cancer types and for other clinically relevant chemotherapeutics used with electrochemotherapy is unknown. Here, we evaluated in vitro in the B16-F10, 4T1 and CT26 murine tumor cell lines, the electrochemotherapy triggered changes in the ICD-associated damage-associated molecular patterns (DAMPs): Calreticulin (CRT), ATP, High Mobility Group Box 1 (HMGB1), and four immunologically important cellular markers: MHCI, MHC II, PD-L1 and CD40. The changes in these markers were investigated in time up to 48 h after ECT. We showed that electrochemotherapy with all three tested chemotherapeutics induced ICD-associated DAMPs, but the induced DAMP signature was cell line and chemotherapeutic concentration specific. Similarly, electrochemotherapy with CDDP, OXA or BLM modified the expression of MHC I, MHC II, PD-L1 and CD40. The potential of electrochemotherapy to change their expression was also cell line and chemotherapeutic concentration specific. Our results thus put the electrochemotherapy with clinically relevant chemotherapeutics CDDP, OXA and BLM on the map of ICD inducing therapies. |
|---|
| Keywords: | electrochemotherapy, cisplatin, immune response |
|---|
| Publication status: | Published |
|---|
| Publication version: | Version of Record |
|---|
| Submitted for review: | 31.03.2023 |
|---|
| Article acceptance date: | 27.04.2023 |
|---|
| Publication date: | 30.04.2023 |
|---|
| Publisher: | MDPI |
|---|
| Year of publishing: | 2023 |
|---|
| Number of pages: | str. 925-1-925-22 |
|---|
| Numbering: | Vol. 11, no. 5 |
|---|
| Source: | Basel, Switzerland |
|---|
| PID: | 20.500.12556/DiRROS-18510  |
|---|
| UDC: | 602 |
|---|
| ISSN on article: | 2076-393X |
|---|
| DOI: | 10.3390/vaccines11050925 |
|---|
| COBISS.SI-ID: | 151344131 |
|---|
| Copyright: | by Authors |
|---|
| Note: | Nasl. z nasl. zaslona;
Opis vira z dne 9. 5. 2023;
|
|---|
| Publication date in DiRROS: | 21.03.2024 |
|---|
| Views: | 91 |
|---|
| Downloads: | 49 |
|---|
| Metadata: |     |
|---|
|
:
|
Copy citation |
|---|
| | | | Share: |  |
|---|
Hover the mouse pointer over a document title to show the abstract or click
on the title to get all document metadata. |
